Molecular targeted therapy for renal cell carcinoma
Mizutani, Y.; Nakanishi, H.; Mizuno, M.; Yoshida, J.; Miki, T.
Hinyokika Kiyo. Acta Urologica Japonica 54(1): 53-56
2008
ISSN/ISBN: 0018-1994 PMID: 18260362 Document Number: 616833
Renal cell carcinoma (RCC) accounts for approximately 2% of all cancer cases worldwide. Metastatic disease is often present at the time of diagnosis of RCC and its poor response to chemotherapy and radiotherapy causes poor prognosis. Immunotherapy is relatively effective for RCC, but the response rate is approximately 15-20%. Therefore, new therapeutic approaches are necessary for these patients with metastatic RCC. Recently, the mechanisms responsible for the growth of RCC have been clarified, and molecular targeted therapy has been developed. In this paper, we review the new molecular targeted therapeutic agents effective for RCC.